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Abstract: Increased intracardiac filling pressure or congestion causes symptoms and leads to 
hospital admissions in patients with heart failure, regardless of their systolic function. A history of 
hospital admission, in turn, predicts further hospitalizations and morbidity, and a higher number 
of hospitalizations determine higher mortality. Congestion is therefore the driving force of the 
natural history of heart failure. Congestion is the syndrome shared by heart failure with preserved 
and reduced systolic function. These two conditions have almost identical morbidity, mortality, 
and survival because the outcomes are driven by congestion. A small difference in favor of heart 
failure with preserved systolic function comes from decreased ejection fraction and left ventricular 
remodeling which is only present in heart failure with decreased systolic function. The magnitude 
of this difference reflects the contribution of decreased systolic function and ventricular remodeling 
to the progression of heart failure. The only treatment available for congestion is fluid removal via 
diuretics, ultrafiltration, or dialysis. It is the only treatment that works equally well for heart failure 
with reduced and preserved systolic function because it affects congestion, the main pathogenetic 
feature of the disease. Diuretics are pathogenetic therapy for heart failure.
Keywords: heart failure, diuretics, congestion, systolic function, diastolic function, ejection   
fraction
To the memory of Kenneth Lee Baughman
Introduction
In the classic paradigm of heart failure, the downward spiral of disease   progression 
starts with decreased cardiac output, resulting in kidney hypoperfusion with the activation 
of the renin–angiotensin–aldosterone axis, retention of sodium and water, stimulation 
of the sympathetic nervous system, vasoconstriction, and further   hypoperfusion. This 
concept works well if an initial offense such as acute   myocardial infarction, myocarditis, 
or idiopathic cardiomyopathy jeopardizes myocardial   contractility. However, these cases 
do not represent the whole spectrum of heart failure. In fact, they represent only about 
half of all heart failure.
About one third to one half of heart failure patients have normal systolic function on the 
basis of left ventricular ejection fraction. Patients with heart failure with preserved systolic 
function do not have decreased cardiac output, and so do not fit into the classic paradigm 
of heart failure. One hypothesis explaining the origin of heart failure in these subsets of 
patients is based on the concept of decreased “effective blood flow”.1 However, several 
studies by Maurer et al provided the evidence that blood flow is normal or increased in a 
substantial number of patients with heart failure with preserved systolic function.2,3International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Multiple studies have compared the natural course, 
morbidity, and mortality in heart failure with preserved and 
reduced systolic function. Patients with preserved ejection 
fraction are usually older, more frequently women, have less 
coronary disease and myocardial infarction, and have more 
atrial fibrillation and other comorbidities. They have higher 
systolic blood pressures and pulse pressures,4 as well as a 
higher prevalence of left ventricular hypertrophy, aortic valve 
disease, and anemia.5
Despite multiple dissimilarities in patient populations, the 
reported mortality is either similar5–11 or somewhat better in 
those with preserved systolic function.12,13 In fact, the   survival 
curves are identical in some studies, indicating that it is 
basically the same condition with the same natural course.
Symptoms in heart failure with preserved and reduced 
systolic function are similar, physical examination is also 
similar, and peak oxygen consumption (VO2) and the 
slope of the ventilation/carbon dioxide production ratio 
on the   cardiopulmonary stress test is indistinguishable.14 
Even the financial burden is similar, in that patients with heart 
failure and normal ejection fraction consume as many health 
care resources as those with reduced ejection fraction.15
These observations can be explained only if we accept 
that the two groups of patients share a common syndrome 
which determines the course and prognosis to a much 
greater extent than all the dissimilarities, including systolic 
function. All the evidence indicates that this syndrome is 
congestion.
Congestion causes heart failure 
symptoms regardless of ejection 
fraction
According to the Acute Decompensated Heart Failure 
National Registry (ADHERE), most patients admitted for 
heart failure are “wet” or congested, with dyspnea, rales, 
edema, radiological signs of fluid overload, or a   combination 
of these features.16 Current technologies providing continuous 
hemodynamic monitoring support these clinical observations 
with hard data from the measured parameters.
During heart failure exacerbations, right ventricular 
pressures increase by about 25%, starting several days 
prior to clinical deterioration. Heart failure   management 
guided by this information resulted in reduction of hospi-
talizations, which dropped from 1.08 per patient-year to 
0.47 per patient-year (57% reduction, P , 0.01).17 Similar 
hemodynamic changes were reported from the Chronicle 
Offers Management to Patients with Advanced Signs and 
Symptoms of Heart Failure trial (COMPASS-HF), in which 
New York Heart Association (NYHA) III or IV patients were 
monitored by a Chronicle® implantable cardioverter device. 
In patients with normal and decreased systolic function, which 
differed according to multiple structural and hemodynamic 
parameters, the mechanism of exacerbation was exactly the 
same, ie, intracardiac pressures increased significantly before 
clinically evident volume overload episodes, and the percent-
age of pressure change from baseline was similar.18 Further-
more, successful treatment of acute decompensated heart 
failure, regardless of systolic function, was associated with 
a decrease in diastolic pressures.19 In summary, congestion is 
a syndrome shared by  heart failure with normal and reduced 
systolic function. Congestion not only causes symptoms, but 
it also worsens the prognosis.
Congestion causes pulmonary 
hypertension and cardiorenal 
syndrome
Two syndromes, ie, pulmonary hypertension and cardiorenal 
syndrome, are consistently associated with a poor prognosis 
in heart failure. Increased pulmonary pressure is linked to 
increased short-term and long-term mortality in heart failure. 
A 5-mmHg increase in right ventricular systolic pressure 
results in a 9% increase in mortality in heart failure with 
both normal and reduced ejection fraction.20 Increased right 
ventricular systolic pressure is a stronger predictor of death 
than left ventricular ejection fraction.21
Several studies have indicated that the severity of 
diastolic rather than systolic cardiac dysfunction determines 
the degree of elevation of pulmonary arterial pressure. 
In individuals with normal ejection fraction and unknown 
heart failure status, mean pulmonary artery pressure was 
shown to be 31.1 ± 6 mmHg in normal diastolic function, 
35.6 ± 10.2 mmHg in Grade 1 diastolic dysfunction (impaired 
relaxation), 38.9 ± 10.6 mmHg in Grade 2 (pseudonormal), 
and 55.1 ± 11.4 mmHg (P , 0.001) in Grade 3 (restrictive 
pattern).22 In untreated patients with dilated cardiomyopathy, 
the E wave deceleration rate and the degree of mitral 
regurgitation were the strongest independent predictors of 
pulmonary hypertension, while ejection fraction was only a 
minor contributor. The reversal of pulmonary hypertension 
after treatment with an angiotensin-converting enzyme 
inhibitor and diuretics occurred only in patients whose 
diastolic left ventricular function improved from restrictive 
or pseudonormal to impaired relaxation pattern.23
In left ventricular systolic dysfunction, pulmonary artery 
systolic pressure was elevated on echocardiography in most 
patients, ranging from 23 to 87 mmHg, and correlated with International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
93
Diuretic therapy for CHF
parameters of diastolic dysfunction. Ejection fraction was not 
an independent predictor of pulmonary artery pressure.24
Cardiorenal syndrome also worsens the prognosis in heart 
failure. In ADHERE, 60% of patients had moderate or severe 
renal insufficiency. Mortality rates, length of hospitaliza-
tion, need for mechanical ventilation, intensive care, and 
cardiopulmonary resuscitation all increase with the degree 
of baseline renal dysfunction.25
Mortality associated with renal dysfunction was higher 
in those with heart failure with normal rather than reduced 
systolic function.26 The presence of at least moderate tricuspid 
regurgitation was associated with a lower glomerular 
filtration rate in heart failure, indicating that elevated renal 
venous pressure plays a role in cardiorenal syndrome.27 In the 
Cleveland Clinic cohort, heart failure patients with worsening 
renal function had higher central venous pressure, both upon 
admission and after intensive medical therapy.   Furthermore, 
the ability of central venous pressure to predict renal 
dysfunction was consistent across the spectrum of systemic 
blood pressure, pulmonary capillary wedge pressure, cardiac 
index, and estimated glomerular filtration rates.28
In summary, two conditions, ie, pulmonary hypertension 
and renal dysfunction, worsen the clinical course and 
  prognosis in heart failure, and develop as a result of elevated 
filling pressures, or congestion.
Congestion worsens the course  
and prognosis in heart failure
Hospitalizations for heart failure occur due to volume 
overload or congestion. It was recently demonstrated that 
the risk of further hospitalizations and death increases 
progressively and independently with each episode of heart 
failure exacerbation, and the total number of heart failure 
hospitalizations is a strong predictor of mortality.29,30 When 
pulmonary hypertension secondary to volume   overload is 
present in chronic hemodialysis patients, it predicts high 
mortality.31 Any sign of congestion adds to mortality. 
Mortality rates almost double from no signs to three or 
more signs of congestion (11% versus 20%,   respectively; 
P , 0.0001).32
The relationship between congestion and systolic function 
may be more complex than is currently thought.   Myocardium 
easily accumulates interstitial fluid, and the resulting 
myocardial edema compromises contractility.33 Extrapolating 
these findings, one can conclude that congestion, regardless 
of its origin, can result in decreased systolic function.
Congestion can facilitate electric instability of the heart. 
Elevated brain natriuretic peptide produced by a stretched 
cardiac muscle has been associated with sudden cardiac death 
in hypervolemic patients.34 Additional confirmation of the 
profound pathophysiological role of congestion can also be 
found in echocardiography.
Severity of congestion reflected in 
diastolic but not systolic dysfunction
In daily clinical practice, left ventricular systolic function 
is often estimated using ejection fraction, yet little evidence 
supports the correlation of ejection fraction with actual 
hemodynamic parameters. In acute heart failure patients, 
only a weak correlation was found between cardiac 
index and ejection fraction (r = 0.25; P = 0.0003), and no 
correlation existed between ejection fraction and wedge 
pressure.35 In another study, measurements of left ventricular 
  systolic performance, ie, stroke work, ejection fraction, and 
contractility by dP/dt, did not differ significantly between 
patients with heart failure with normal systolic function and 
normal controls. The authors concluded that the underlying 
pathophysiology causing symptoms and signs of heart failure 
did not reflect abnormalities in left ventricular systolic 
properties, but more likely abnormalities in diastolic function, 
which was the predominant and necessary factor for the 
occurrence of heart failure in these patients.36
Unlike ejection fraction, diastolic dysfunction on 
echocardiography is closely correlated with intracardiac 
filling pressures. Abnormal echocardiographic diastolic 
parameters, especially an elevated E/e’ ratio (ratio of peak 
velocity of early diastolic inflow to early diastolic mitral 
annular velocity), indicate elevated filling pressures.37–44 In a 
large population-based study, patients with heart failure and 
preserved systolic function in Olmsted County, Minnesota, 
had markedly different left ventricular end-diastolic pressure 
and diastolic echo parameters, especially E/e’, compared 
with both normal controls and hypertensive patients, whereas 
cardiac index was similar in all three cohorts.45
A high E/e’ ratio reflects elevated intracardiac   pressures, 
regardless of etiology of heart failure and ejection   fraction. 
Elevated filling pressures in healthy hearts produce a 
restrictive pattern on echocardiography. When intravenous 
fluids were given to healthy dogs, their echoes demonstrated 
restrictive left ventricular filling.46
Interestingly, in patients with very advanced systolic 
heart failure, the correlation between E/e’ and wedge pres-
sure becomes weaker. In a recent series from Cleveland 
Clinic, no correlation was found between E/e’ ratio and 
wedge pressure in patients with larger left ventricular vol-
umes, severely reduced cardiac indexes, or biventricular International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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pacemakers.47 This likely means that congestion becomes 
less important than low cardiac output in very advanced 
heart failure.
Diastolic dysfunction predicts  
poor prognosis regardless  
of systolic function
Diastolic dysfunction predicts the prognosis in heart failure 
patients with both normal and decreased ejection fraction. 
In systolic heart failure, the primary endpoint of death, trans-
plantation, or heart failure hospitalization was independently 
predicted by parameters of diastolic function, including 
shorter deceleration time, a lower ratio of pulmonary vein 
systolic to diastolic velocity, and increased E/e’ levels.48,49 
In another study, the mitral E/e’ ratio (P , 0.001) and the 
Tei index (index of myocardial performance incorporating 
both systolic and diastolic time) but not the ejection fraction, 
were the only independent predictors of death or heart failure 
admission (P = 0.019).50 Within a cohort with severely 
decreased ejection fraction #30%, diastolic indexes of mitral 
inflow significantly predicted poor outcomes, while ejection 
fraction did not.51 A restrictive filling pattern was the only 
independent predictor of death or appropriate defibrillator 
shock.52 In pooled data from 3540 patients with heart failure 
across the entire spectrum of ejection fraction, a restrictive 
filling pattern was associated with a twofold increase in the 
risk of death, and was independent of ejection fraction, class, 
and age.53 Diastolic dysfunction is also strongly and inversely 
associated with exercise capacity. Patients with a high E/e’ 
have reduced exercise tolerance.54
Different studies have demonstrated that elevation of 
brain natriuretic peptide either correlates better with diastolic 
dysfunction than with systolic dysfunction, or correlates 
only with diastolic dysfunction, and does not correlate with 
ejection fraction at all.55
In summary, advanced diastolic dysfunction reflects the 
severity of congestion, and predicts morbidity and mortality 
in heart failure patients regardless of ejection fraction.
Heart failure exists without systolic 
dysfunction, but not without 
diastolic dysfunction
Although approximately 30%–50% of patients with heart 
failure have normal systolic function, hardly any heart 
  failure patients have normal diastolic function. In a series of 
206 patients with clinical heart failure, diastolic dysfunction 
by echocardiography was present in .90%, regardless of 
ejection fraction.55 In another series of 126 heart failure 
patients with ejection fraction ,35%, none had normal 
diastolic function.56
In the Olmstead County heart failure cohort, only 10% 
of patients with preserved ejection fraction and 5% of those 
with reduced ejection fraction had normal diastolic function.6 
In another study that enrolled randomly selected residents 
rather than heart failure patients, only one in 45 participants 
with a validated diagnosis of heart failure had normal diastolic 
function. In participants with an ejection fraction ,50%, only 
one fifth (20.5%) had normal diastolic function.57
According to the Mayo Clinic algorithm for   diagnosing 
diastolic dysfunction,58 ejection fraction ,50% is not compat-
ible with normal diastolic function. If the E/A ratio is   normal, 
it immediately places the patient in the “  pseudonormal” range 
and presumes elevated filling pressures.
In summary, while systolic dysfunction may or may not 
be present in heart failure, diastolic dysfunction is universal. 
It reflects the presence of congestion which is common to 
heart failure with any degree of systolic function.
Heart failure with reduced  
and preserved ejection fraction
Comparison of heart failure with preserved and reduced 
systolic function demonstrates that disease progression in 
these two cohorts is strikingly similar. A slight difference in 
the natural course and prognosis in favor of preserved systolic 
function has at least two explanations. The first one has to do 
with patient selection. In all the relevant published studies, 
patients were diagnosed as having heart failure with preserved 
systolic function according to clinical, most commonly the 
Framingham, criteria. Left ventricular filling pressure was 
neither measured by catheterization nor estimated by diastolic 
dysfunction on echocardiography. This could result in over-
diagnosis of heart failure. In a study by Caruana et al,59 102 of 
109 patients with normal ejection fraction diagnosed with 
heart failure by their internists had other conditions, including 
obesity, chronic obstructive pulmonary disease, and coronary 
artery disease, that could explain their symptoms, and only 
seven had heart failure. It is also possible that some cohorts 
representing heart failure with preserved systolic function 
are contaminated by patients having conditions other than 
heart failure. These patients may be partially responsible for 
slightly more favorable outcomes.
However, there is another factor determining the difference. 
Decreased ejection fraction and left ventricular remodeling 
are present in heart failure with reduced systolic function, but International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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are absent in preserved systolic function. Decreased ejection 
fraction and left ventricular remodeling creates an excess 
mortality in heart failure with reduced systolic function. 
It adds electrical instability, leading to a higher rate of 
sudden cardiac death, in this subset of patients. Sudden 
cardiac death occurs more frequently in those with decreased 
ejection fraction than in those with normal ejection fraction 
(21% versus 16%, respectively),60 or even versus 2% as per 
the Duke Databank for Cardiovascular Disease.61
The ultimate treatment for heart failure with reduced 
systolic function is a left ventricular assist device or heart 
transplantation, which is practically never utilized in heart 
failure with normal systolic function, except for specific cases 
of restrictive or hypertrophic obstructive cardiomyopathy. 
It is likely that, at some point in time, left ventricular dilata-
tion and remodeling reaches a critical limit and becomes 
the driving force of the downward spiral of terminal heart 
failure. The angiotensin-converting enzyme inhibitors and 
beta-blockers work in systolic heart failure because they 
slow down and partially reverse left ventricular remodeling. 
Without such remodeling, as in heart failure with preserved 
systolic function, they do not have a substrate to work on. 
All clinical trials testing drugs used successfully in reduced 
ejection fraction failed to demonstrate their benefit in the 
subset with preserved systolic function. The difference in 
morbidity and mortality between heart failure with preserved 
and reduced ejection fraction measures the contribution of 
the low output syndrome, together with electric instability 
created by left ventricular remodeling, to the natural course 
of heart failure.
Advances in heart failure treatment from 1991 to 2001 
have led to better survival in patients with reduced, but not 
preserved, systolic function. The one-year survival rate 
trended toward worsening in the preserved systolic function 
group, but improved in the group with depressed ejection 
fraction (from 87.7% to 81.0% and from 76% to 84%, 
respectively).62 This occurred because, while new treatment 
modalities were implemented for left ventricular remodeling 
and sudden cardiac death (features unique to heart failure 
with decreased systolic function), treatment for congestion 
remained the same, ie, with diuretics.
Diuretics are the universal 
treatment for heart failure
If the common denominator of heart failure is decreased 
output, the mainstay of heart failure treatment should be 
inotropic agents. However, the role of inotropes in heart 
failure is limited. They are mostly used at the extreme of 
the heart failure spectrum, ie, those with severely impaired 
systolic function.
Because the common feature of heart failure is congestion, 
the mainstay of heart failure treatment is   decongestion, or 
diuretics. In inpatient or outpatient settings and in systolic 
or diastolic heart failure, diuretics are invariably the top 
prescribed drug. In ADHERE, diuretics were used in 
64.8% and 65.5% on hospital admission, 67% and 78.8% 
  during hospitalization, and 79.5% and 83.7% on discharge 
in patients with heart failure with preserved and reduced 
ejection fraction, respectively.63
Several studies have attempted to randomize heart failure 
patients to diuretics or no diuretics, primarily through diuretic 
withdrawal in patients with already established treatment for 
heart failure. Richardson et al,64 Cowley et al,65 van Kraaij et al,66 
Mathur et al,67 Andrews et al,68 and Grinstead et al69 have all 
demonstrated that patients with heart failure deteriorate so 
quickly after discontinuation of diuretics that they have to be 
reinstituted on diuretic therapy within weeks.
Richardson et al64 substituted captopril for furosemide 
in symptomatic heart failure in a double-blind, randomized 
study. Of 14 patients taken off diuretics, four (28.6%) 
developed pulmonary edema or severe dyspnea and required 
immediate reinstitution of furosemide within eight weeks. 
In another study, patients who were on diuretics for heart 
failure could only tolerate withdrawal of this medication for 
a median duration of six weeks.66 Mathur et al67 conducted 
a randomized, double-blind, crossover, placebo-controlled 
trial lasting 16 weeks and found that none of the heart failure 
patients included could stay off diuretics. Grinstead et al69 
demonstrated that 20 (71%) of 41 stable heart failure patients 
taken off diuretics and randomized to lisinopril or placebo 
had to be restarted on diuretics due to worsening congestion 
within 12 weeks (median 15 days), with no difference 
between the lisinopril and placebo arms of the study. Finally, 
a meta-analysis of loop diuretics in heart failure found a 
statistically significant survival benefit of these drugs, even 
though many studies included in this analysis did not enroll 
patients with symptomatic heart failure, as demonstrated in 
a previous review.70
Several studies, most of which were retrospective, dem-
onstrated that use of diuretics or higher doses of diuretics 
are associated with a poorer prognosis in general and higher 
mortality in particular, even after adjustments for multiple 
comorbidities.71–73 In none of these studies were patients 
randomized to receive loop diuretics versus no diuretics or International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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placebo. Loop diuretics were prescribed by the physician 
guided by symptoms, ie, congestion. Simple adjustment 
for NYHA class cannot correct this selection bias because 
NYHA classification takes into account primarily signs of 
left ventricular dysfunction (dyspnea) but does not include 
edema, ascites, and anasarca, which reflect primarily right 
ventricular failure. Meanwhile, diuretics are prescribed for 
both conditions. Therefore, the diuretic dose reflects the 
severity of heart failure better than all other comorbidities 
taken together because the empiric dose of loop diuretics 
is matched to the severity of congestion. In the absence 
of directly measured intracardiac pressures, the dose of 
loop diuretics is the best measure of congestion we have. 
The higher the requirement for diuretics, the higher is the 
morbidity and mortality. No large prospective, randomized, 
placebo-controlled trials in heart failure have justified the 
use of diuretics. Such trials cannot be conducted because 
patients with heart failure do not survive without diurectics. 
A recent subanalysis of the Evaluation Study of Congestive 
Heart Failure and Pulmonary Artery Catheterization Effec-
tiveness study (ESCAPE) demonstrated reduced mortality in 
patients with systolic heart failure undergoing more aggres-
sive diuresis, even though this was achieved at the cost of 
worsening renal function.74
Conclusion
Heart failure as a syndrome develops when there is an 
elevation in left ventricular filling pressure. Clinically it 
presents as congestion, regardless of etiology and systolic 
function. Congestion is a common denominator shared 
by all patients with heart failure. It can be identified inva-
sively by direct measurement of intracardiac pressures, or 
  noninvasively by signs of diastolic dysfunction on echocar-
diography. The severity of congestion determines symptoms, 
morbidity, natural course of the disease, and mortality in heart 
  failure, as well as major complications, including   pulmonary 
hypertension and cardiorenal syndrome. The best available 
  treatment for congestion is diuretics which work equally 
well in heart failure with preserved and reduced systolic 
function.
Many patients with heart failure develop elevated left 
ventricular filling pressures and congestion as a result of 
decreased systolic function. Their natural course is some-
what worse because, in addition to congestion, they have left 
ventricular remodeling and decreased cardiac output, as well 
as electrical instability, resulting in ventricular tachycardia, 
ventricular fibrillation, and sudden cardiac death. Besides 
diuretics, they can benefit from other treatments either 
reversing left ventricular remodeling or preventing sudden 
cardiac death, including angiotensin-converting enzyme 
inhibitors, beta-blockers, aldosterone antagonists, cardiac 
resynchronization therapy, defibrillators, left ventricular 
assist devices, and heart transplantation.
Further advances in heart failure treatment should be 
expected from better monitoring of intracardiac pressures and 
more accurate and timely decongestion. This will improve 
the clinical course of all heart failure patients with normal or 
decreased ejection fraction. It will also result in less severe 
complications, eg, cardiorenal syndrome and pulmonary 
hypertension, which could further improve survival. Clini-
cal trials targeting these syndromes should not focus only 
on patients with preserved or reduced systolic function but 
rather on all heart failure population.
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